Open Access Te Herenga Waka-Victoria University of Wellington
Browse

Investigating the Role of a Novel Kappa Opioid Receptor Agonist in Functional Recovery in the Augmented Cuprizone Model of Demyelination and Its Side Effects

Download (2.79 MB)
thesis
posted on 2025-01-26, 21:55 authored by Sheein Hong

Multiple sclerosis (MS) is a debilitating neuroinflammatory disease that affects 2.8 million people worldwide. Myelin-specific peripheral lymphocytes infiltrate the central nervous system (CNS) and destroy the myelin sheath, causing further inflammatory damage and demyelination, closely followed by axonal injury and death. These events lead to lesion formation, which accumulates in number over time and results in symptoms that severely impact quality of life. There is no cure for MS and immunomodulatory therapies are used to help manage the disease. However, these are unable to promote recovery, are limited to slowing disease progression, and are ineffective for progressive forms of MS. Due to the lack of treatment options that promote recovery, researchers look towards therapeutic targets that promote remyelination.

Recent preclinical studies have presented the kappa opioid receptor (KOPr) as a promising target for the promotion of remyelination and potential treatment of multiple sclerosis. Most remyelination studies have used the KOPr agonist, U50,488, to demonstrate the promotion of remyelination through KOPr activation. This has been done through in vitro cell cultures as well as in vivo preclinical models of demyelination that mimic aspects of MS, by promoting oligodendrocyte precursor cell (OPC) differentiation to mature oligodendrocytes. However, the clinical use of KOPr agonists is limited due to the associated unpleasant side effects, such as dysphoria, anxiety, and sedation.

In this thesis, we used the novel KOPr agonist LDK-276, an analogue of U50,488, alongside the only clinically available KOPr agonist, nalfurafine, to preliminarily test its efficacy in promoting functional recovery in an improved augmented cuprizone model of extensive demyelination, using cuprizone and rapamycin (cupR) intoxication. To quantify and evaluate the efficacy of KOPr activation in functional recovery, we used the mouse motor skill sequence (MOSS) longitudinal to the augmented cuprizone model to quantify non evoked measures of home-age activity. No functional recovery was observed in cupR mice that were treated with LDK-276.

To evaluate whether LDK-276 causes some of the unpleasant side effects associated with KOPr agonists, we used behavioural side effect assays, alongside U50,488, to assess sedative effects, motor coordination, and locomotor deficit side effects. No undesirable side effects were identified in LDK-276 with these behavioural tests. LDK-276 has previously shown potential in promoting remyelination through an in vitro assay, so further investigation of its efficacy in remyelination and functional recovery may be beneficial.

History

Copyright Date

2022-11-22

Date of Award

2022-11-22

Publisher

Te Herenga Waka—Victoria University of Wellington

Rights License

Author Retains All Rights

Degree Discipline

Biomedical Science

Degree Grantor

Te Herenga Waka—Victoria University of Wellington

Degree Level

Masters

Degree Name

Master of Biomedical Science

ANZSRC Type Of Activity code

1 Pure basic research

Victoria University of Wellington Item Type

Awarded Masters Thesis

Language

en_NZ

Victoria University of Wellington School

School of Biological Sciences

Advisors

Kivell, Bronwyn